KR100871489B1 - 카할라이드 화합물 - Google Patents

카할라이드 화합물 Download PDF

Info

Publication number
KR100871489B1
KR100871489B1 KR1020027010355A KR20027010355A KR100871489B1 KR 100871489 B1 KR100871489 B1 KR 100871489B1 KR 1020027010355 A KR1020027010355 A KR 1020027010355A KR 20027010355 A KR20027010355 A KR 20027010355A KR 100871489 B1 KR100871489 B1 KR 100871489B1
Authority
KR
South Korea
Prior art keywords
val
allo
thr
ile
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027010355A
Other languages
English (en)
Korean (ko)
Other versions
KR20020092951A (ko
Inventor
페르난도 알베리시오
어네스트 히랄트
호세 깔로스 히메네즈
안헬 로페즈
이그나시오 만자나레스
이그나시오 로드리게스
미리암 로요
Original Assignee
파르마 마르, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르, 에스.에이. filed Critical 파르마 마르, 에스.에이.
Publication of KR20020092951A publication Critical patent/KR20020092951A/ko
Application granted granted Critical
Publication of KR100871489B1 publication Critical patent/KR100871489B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
KR1020027010355A 2000-02-09 2001-02-09 카할라이드 화합물 Expired - Fee Related KR100871489B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0002952.0 2000-02-09
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds

Publications (2)

Publication Number Publication Date
KR20020092951A KR20020092951A (ko) 2002-12-12
KR100871489B1 true KR100871489B1 (ko) 2008-12-05

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027010355A Expired - Fee Related KR100871489B1 (ko) 2000-02-09 2001-02-09 카할라이드 화합물

Country Status (27)

Country Link
US (2) US7482429B2 (enExample)
EP (3) EP2258715A1 (enExample)
JP (1) JP5188665B2 (enExample)
KR (1) KR100871489B1 (enExample)
CN (2) CN101597326B (enExample)
AT (1) ATE371667T1 (enExample)
AU (1) AU783542B2 (enExample)
BG (1) BG65926B1 (enExample)
BR (1) BR0108213A (enExample)
CA (1) CA2399187C (enExample)
CY (1) CY1106992T1 (enExample)
CZ (1) CZ304258B6 (enExample)
DE (1) DE60130192T2 (enExample)
DK (1) DK1254162T3 (enExample)
ES (1) ES2292558T3 (enExample)
GB (1) GB0002952D0 (enExample)
HU (1) HUP0301817A3 (enExample)
IL (2) IL150981A0 (enExample)
MX (1) MXPA02007760A (enExample)
NO (1) NO331847B1 (enExample)
NZ (1) NZ520488A (enExample)
PL (1) PL207121B1 (enExample)
PT (1) PT1254162E (enExample)
RU (1) RU2280039C2 (enExample)
SK (1) SK11242002A3 (enExample)
UA (1) UA76949C2 (enExample)
WO (1) WO2001058934A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
ES2256305T3 (es) 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
EP2207561A2 (en) * 2007-10-19 2010-07-21 Pharma Mar, S.A. Improved antitumoral treatments
WO2009095480A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
KR102378845B1 (ko) 2017-03-30 2022-03-24 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
KR20250159079A (ko) 2019-12-20 2025-11-07 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
EP4167971A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
EP4167966A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
WO2023205241A1 (en) 2022-04-21 2023-10-26 Zevra Therapeutics, Inc. Gamma-hydroxybutyrate delivering compounds and processes for making and using them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
JP2902115B2 (ja) * 1991-11-19 1999-06-07 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規アミリン作動薬ペプチドおよびその使用
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050406A1 (en) * 1997-05-09 1998-11-12 The General Hospital Corporation Cell proliferation related genes
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
PT1131304E (pt) * 1998-11-19 2003-04-30 Warner Lambert Co N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il|-acrilamida um inibidor irreversivel de tirosino quinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2001255575B2 (en) * 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
ES2256305T3 (es) 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. ORG. CHEM, Vol.61 : 6594-6600 (1996)
Tetrahedron Lett. Vol.41:9765-9769 (2000.12.)
Tetrahedron Lett. Vol.55:7739-7746 (1999)

Also Published As

Publication number Publication date
CA2399187A1 (en) 2001-08-16
HUP0301817A2 (hu) 2003-09-29
DK1254162T3 (da) 2008-01-02
AU783542B2 (en) 2005-11-10
US7482429B2 (en) 2009-01-27
NZ520488A (en) 2005-03-24
KR20020092951A (ko) 2002-12-12
UA76949C2 (en) 2006-10-16
IL150981A (en) 2013-05-30
EP1829889A3 (en) 2007-09-26
HK1047290A1 (en) 2003-02-14
BG107020A (bg) 2003-05-30
WO2001058934A2 (en) 2001-08-16
AU3208601A (en) 2001-08-20
CY1106992T1 (el) 2012-09-26
DE60130192T2 (de) 2008-05-21
EP1829889A2 (en) 2007-09-05
ATE371667T1 (de) 2007-09-15
PT1254162E (pt) 2007-12-03
SK11242002A3 (sk) 2003-06-03
BR0108213A (pt) 2003-03-05
CN1422278A (zh) 2003-06-04
EP1254162B1 (en) 2007-08-29
WO2001058934A3 (en) 2002-03-21
JP5188665B2 (ja) 2013-04-24
HUP0301817A3 (en) 2011-10-28
RU2280039C2 (ru) 2006-07-20
CZ304258B6 (cs) 2014-02-05
CA2399187C (en) 2011-04-19
EP2258715A1 (en) 2010-12-08
GB0002952D0 (en) 2000-03-29
CN101597326A (zh) 2009-12-09
DE60130192D1 (de) 2007-10-11
NO331847B1 (no) 2012-04-23
CN101597326B (zh) 2014-07-09
ES2292558T3 (es) 2008-03-16
EP1254162A2 (en) 2002-11-06
MXPA02007760A (es) 2002-10-23
JP2003522198A (ja) 2003-07-22
PL207121B1 (pl) 2010-11-30
US20080318849A1 (en) 2008-12-25
PL356800A1 (en) 2004-07-12
IL150981A0 (en) 2003-02-12
RU2002123877A (ru) 2004-01-10
NO20023749D0 (no) 2002-08-08
NO20023749L (no) 2002-10-07
CZ20022740A3 (cs) 2003-01-15
BG65926B1 (bg) 2010-05-31
US20040214755A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
KR100871489B1 (ko) 카할라이드 화합물
WO2012173846A2 (en) Peptidomimetic macrocycles
EP1373305B1 (en) Process for producing trunkamide a compounds
EP4578867A1 (en) Cyclic peptide or salt thereof and mdmx inhibitor
AU2002251221A1 (en) Process for producing trunkamide A compounds
Albericio et al. Kahalalide F and related compounds
HK1047290B (en) Kahalalide f and related compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121107

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20131108

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20141106

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20151106

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161126

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161126